Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)

NCT04947319 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

119

Enrollment

INDUSTRY

Sponsor class

Conditions

Refractory Primary Central Nervous System Lymphoma
Primary CNS Lymphoma

Interventions

DRUG: Tirabrutinib
DRUG: Tirabrutinib
DRUG: Tirabrutinib

Sponsor

Ono Pharmaceutical Co., Ltd.